Expression of the cellular oxygen sensor PHD2 EGLN-1 predicts radiation sensitivity in squamous cell cancer of the head and neck

International Journal of Radiation Biology

Volumn 85, Issue 10, 2009, Pages 900-908

  Luukkaa, Marjaana ^a   Jokilehto, Terhi ^b   Kronqvist, Pauliina ^a   Vahlberg, Tero ^b   Grénman, Reidar ^a   Jaakkola, Panu ^a,b   Minn, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Headneck squamous cell carcinoma; HIF hydroxylases; Hypoxia; Prognostic factors; Prolyl hydroxylase; Radiotherapy

Indexed keywords

PROLYLHYDROXYLASE DOMAIN PROTEIN 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURGERY; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MALE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROCOLLAGEN-PROLINE DIOXYGENASE; PROGNOSIS; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 70350070895     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553000903074104     Document Type: Article

References (54)

1. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH. Semenza GL. 2001. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 61:2911-2916.
2. Bankfalvi A, Piffko J. 2000. Prognostic and predictive factors in oral cancer: The role of the invasive tumour front. Journal of Oral Pathology & Medicine 29:291-298.
3. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. The EMBO Journal 22:4082-4090.
4. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. 1999. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology 53:113-117.
5. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. 1996. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research 56:941-943.
6. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. 1997. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics 38:285-289.
7. Broders AC. 1932. Practical points on the microscopic grading of carcinoma. New York State Journal of Medicine.
8. Brown JM. 2000. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Molecular Medicine Today 6:157-162.
9. Bruick RK, McKnight SL. 2001. A conserved family of Prolyl-4- hydroxylases that modify HIF. Science 294:1337-1340.
10. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, Vijver MJ, Brown PO. 2006. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. Public Library of Science Medicine 3:e47.
11. D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C. 2003. Hypoxia up-regulates prolyl hydroxylase activity: A feedback mechanism that limits HIF-1 responses during reoxygenation. Journal of Biological Chemistry 278:38183-38187.
12. Dunst J, Stadler P, Becker A, Lautenschlager C, PelzT,Hansgen G, MollsM, Kuhnt T. 2003. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlentherapie und Onkologie 179:521-526.
13. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54.
14. Fyles A, Milosevic M, Hedley D, Pintilie M, LevinW,Manchul L, Hill RP. 2002. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. Journal of Clinical Oncology 20:680-687.
15. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature 379:88-91.
16. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. 1953. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British Journal of Radiology 26:638-648.
17. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. 1996. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Research 56:4509-4515.
18. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL. 2002. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research 8:2595-2604.
19. Ishikawa H, Sakurai H, Hasegawa M, Mitsuhashi N, Takahashi M, Masuda N, Nakajima M, Kitamoto Y, Saitoh J, Nakano T. 2004. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics 60:513-521.
20. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292:464-468.
21. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Targeting of HIFalpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472.
22. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM. 2006. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clinical Cancer Research 12:1080-1087.
23. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL. 2002. Hypoxiainducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 53:1192-1202.
24. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. 1996. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. The American Journal of Pathology 148:1567-1576.
25. Kronqvist P, Kuopio T, Collan Y. 1998. Morphometric grading of invasive ductal breast cancer. I. Thresholds for nuclear grade. British Journal of Cancer 78:800-805. (Pubitemid 28418317)
26. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. 2003. Overexpression of hypoxia-inducible-factor 1alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. British Journal of Cancer 89:1042-1047.
27. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. 2002. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861.
28. Lindholm P, Valavaara R, Aitasalo K, Kulmala J, Laine J, Elomaa L, Sillanmaki L, Minn H, Grenman R. 2006. Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: A prospective phase II study. Radiotherapy and Oncology 78:146-151.
29. Luukkaa M, Minn H, Aitasalo K, Kronqvist P, Kulmala J, Pyrhönen S, Grénman R. 2003. Treatment of squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx - an analysis of 174 patients in south western Finland. Acta Oncologica 42:756-762.
30. Marxsen JH. 2004. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochemistry Journal 381:761-767.
31. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ,HankinsonO, PughCW, Ratcliffe PJ. 1997. Hypoxiainducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.Proceedings of the National Academy of Sciences of the USA 94:8104-8109.
32. Nordsmark M, Bentzen SM, Rudat V, BrizelD, Lartigau E, Stadler P, Becker A,AdamM,MollsM,Dunst J, Terris DJ, Overgaard J. 2005. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiotherapy and Oncology 77:18-24.
33. Nordsmark M, Hoyer M, Keller J, Nielsen OS, Jensen OM, Overgaard J. 1996a.The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. International Journal of Radiation Oncology, Biology, Physics 35:701-708.
34. Nordsmark M, Overgaard J. 2000. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology 57:39-43.
35. Nordsmark M, Overgaard M, Overgaard J. 1996b. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 41:31-39.
36. O-charoenrat P, Pillai G, Patel S, Fisher C, Archer D, Eccles S, Rhys- Evans P. 2003.Tumour thickness predicts cervical nodalmetastases and survival in early oral tongue cancer.OralOncology 39:386-390.
37. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 5:649-655.
38. Reynolds TY, Rockwell S, Glazer PM. 1996. Genetic instability induced by the tumor microenvironment. Cancer Research 56:5754-5757.
39. Rudat V, Stadler P, Becker A, Vanselow B, Dietz A, Wannenmacher M, Molls M, Dunst J, Feldmann HJ. 2001. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlentherapie und Onkologie 177:462-468.
40. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, KwasnyW, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G, and the Austrian Breast and Colorectal Cancer Study Group. 2002. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clinical Cancer Research 8:1831-1837.
41. Scully RE, Bonfiglo TA, Kurman RJ, Silverberg SG, Wilkinson EJ. 1994. Histological typing of female genital tract tumours. World Health Organization International Histological Classi- fication of Tumours. 2nd ed. Berlin:Springer-Verlag. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. National Review of Cancer 3:721-732.
42. Semenza GL. 1998. Hypoxia-inducible factor 1: Master regulator of O2 homeostasis. Current Opinion in Genetics & Development 8:588-594.
43. ShanmugaratnamK,SobinLH. 1991.Histological typingof tumours of the upper respiratory tract and ear. International Histological Classification of Tumors. 2nd ed. Berlin: Springer Verlag.
44. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ. 2003. Cyclooxygenase- 2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Research 63:2347-2350.
45. Shweiki D, Itin A, Soffer D, Keshet E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 359:843-845.
46. Sobin LH, Wittekind C. 2002. TNM classification of malignant tumours. International Union Against Cancer (IUCC). 6th ed. New York: Wiley-Liss.
47. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. 2000. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645.
48. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E, Sofras F. 2005. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU International 95:425-431.
49. Volm M, Koomagi R. 2000. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Research 20:1527-1533.
50. Welkoborsky HJ, Hinni M, Dienes HP, Mann WJ. 1995. Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers. The Annals of Otology, Rhinology, and Laryngology 104:503-510.
51. Wenger RH. 2002. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. The FASEB Journal: Official publication of the Federation of American Societies for Experimental Biology 16:1151-1162.
52. Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, Peters HJ, Honess D, Harris AL, Dachs GU, van der Kogel A, Stratford IJ. 2005. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiotherapy and Oncology 75:89-98.
53. Yu F, White SB, Zhao Q, Lee FS. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the USA 98:9630-9635.
54. Yuan J, Glazer PM. 1998. Mutagenesis induced by the tumor microenvironment. Mutation Research 400:439-446.